Second-line treatment outcomes after first-line sunitinib therapy in metastatic renal cell carcinoma

Clinical Genitourinary Cancer

Volumn 10, Issue 4, 2012, Pages 256-261

  Chen, Chi Chang ^a   Hess, Gregory P ^a,b   Liu, Zhimei ^c   Gesme, Dean H ^d   Agarwala, Sanjiv S ^e   Garay, Carlos C ^c   Hill, Jerrold W ^a   Guo, Amy ^c  

^a IQVIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d Minnesota Oncology   (United States)

^e TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Everolimus; Metastatic renal cell carcinoma; Sorafenib; Temsirolimus; Tyrosine kinase inhibitor

Indexed keywords

EVEROLIMUS; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ADULT; ARTICLE; DATA BASE; DECISION MAKING; FEMALE; FOLLOW UP; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; TREATMENT FAILURE; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PYRROLES; RETROSPECTIVE STUDIES; SIROLIMUS; TREATMENT OUTCOME;

EID: 84868515033     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2012.04.006     Document Type: Article

References (19)

1. A.M. Molina, R.J. Motzer Current algorithms and prognostic factors in the treatment of metastatic renal cell carcinoma Clin Genitourin Cancer 6 suppl 1 2008 S7 S13
2. R.J. Motzer New perspectives on the treatment of metastatic renal cell carcinoma: an introduction and historical overview Oncologist 16 suppl 2 2011 1 3
3. E.A. Singer, G.N. Gupta, R. Srinivasan Update on targeted therapies for clear renal cell carcinoma Curr Opin Oncol 23 2011 283 289
4. T.E. Hutson Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence Oncologist 16 suppl 2 2011 14 22
5. A.M. Molina, R.J. Motzer Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow Oncologist 16 suppl 2 2011 45 50
6. D.J. Reeves, C.Y. Liu Treatment of metastatic renal cell carcinoma Cancer Chemother Pharmacol 64 2009 11 25
7. P.J. Wysocki, J. Zolnierek, C. Szczylik Targeted therapy of renal cell cancer Curr Opin Investig Drugs 9 2008 570 575
8. Kidney National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology-v.2.2010 National Comprehensive Cancer Network [Web site] http://www.nccn/org/professionals/physician-gls/PDF/kidney.pdf Accessed: March 1, 2011
9. C.P. Filson, B.G. Redman, R.L. Dunn Initial patterns of care with oral targeted therapies for patients with renal cell carcinoma Urology 77 2011 825 830.e1
10. G. Facchini, F. Perri, M. Caraglia New treatment approaches in renal cell carcinoma Anticancer Drugs 20 2009 893 900
11. B. Escudier, T. Eisen, W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134
12. R.J. Motzer, T.E. Hutson, P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124
13. G. Hudes, M. Carducci, P. Tomczak Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2007 2271 2281
14. B. Escudier, A. Pluzanska, P. Koralewski Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2007 2103 2111
15. R.J. Motzer, B. Escudier, S. Oudard Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449 456
16. J.A. Arranz, M.A. Climent, J.L. González-Larriba Sorafenib in renal cell carcinoma Crit Rev Oncol Hematol 80 2011 314 322
17. T. Powles, S. Chowdhury, R. Jones Sunitinib and other targeted therapies for renal cell carcinoma Br J Cancer 104 2011 741 745
18. G.P. Hess, C. Chen, Z. Liu Metastatic renal cell carcinoma: patient characteristics and recent treatment patterns in real-world practice J Manag Care Pharm 17 2011 261
19. A. Ravaud How to optimise treatment compliance in metastatic renal cell carcinoma with targeted agents Ann Oncol 20 suppl 1 2009 i7 i12